337 related articles for article (PubMed ID: 28361526)
21. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Dietl B; Sánchez I; Arcenillas P; Cuchi E; Gómez L; González de Molina FJ; Boix-Palop L; Nicolás J; Calbo E
Int J Antimicrob Agents; 2018 Mar; 51(3):498-502. PubMed ID: 29158144
[TBL] [Abstract][Full Text] [Related]
22.
Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
[TBL] [Abstract][Full Text] [Related]
23. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
24. [Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii].
Taşbakan MS; Pullukçu H; Ekren PK; Oz AT; Midilli M; Aydemir S; Gürgün A; Başoğlu OK; Bacakoğlu F
Mikrobiyol Bul; 2009 Jan; 43(1):61-70. PubMed ID: 19334381
[TBL] [Abstract][Full Text] [Related]
25. Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Yaita K; Sameshima I; Takeyama H; Matsuyama S; Nagahara C; Hashiguchi R; Moronaga Y; Tottori N; Komatsu M; Oshiro Y; Yamaguchi Y
Intern Med; 2013; 52(12):1407-12. PubMed ID: 23774557
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Sousa Dominguez A; Perez-Rodríguez MT; Nodar A; Martinez-Lamas L; Perez-Landeiro A; Crespo Casal M
J Antimicrob Chemother; 2017 Apr; 72(4):1262-1263. PubMed ID: 27999042
[No Abstract] [Full Text] [Related]
28. Treatment of a complex orthopaedic infection due to extensively drug-resistant
Hassan S; Kahn MD; Saraiya N; Nori P
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305368
[TBL] [Abstract][Full Text] [Related]
29. Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.
Mogyoródi B; Csékó AB; Hermann C; Gál J; Iványi ZD
Sci Rep; 2022 Mar; 12(1):4455. PubMed ID: 35292686
[TBL] [Abstract][Full Text] [Related]
30. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
33. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Craig WA; Andes DR
Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659
[TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
35. Ceftolozane-tazobactam: When, how and why using it?
López Montesinos I; Montero M; Sorlí L; Horcajada JP
Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):35-37. PubMed ID: 34598422
[TBL] [Abstract][Full Text] [Related]
36. Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Oliver WD; Heil EL; Gonzales JP; Mehrotra S; Robinett K; Saleeb P; Nicolau DP
Antimicrob Agents Chemother; 2015 Dec; 60(3):1899-901. PubMed ID: 26711770
[TBL] [Abstract][Full Text] [Related]
37. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
[TBL] [Abstract][Full Text] [Related]
39. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Shortridge D; Castanheira M; Pfaller MA; Flamm RK
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
[TBL] [Abstract][Full Text] [Related]
40. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
Martin-Loeches I; Bruno CJ; DeRyke CA
Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
